Literature DB >> 3367561

Proteinuria in IgA nephropathy.

K Neelakantappa1, G R Gallo, D S Baldwin.   

Abstract

Clinicopathological data in 74 patients with IgA nephropathy were analyzed with special attention to level of proteinuria and its prognostic significance in this disease. Excretion rates exceeding 3 g per day (heavy), in the range of 1 to 2.9 g (moderate) and under 1 g per day (mild) each occurred in approximately equal proportions of patients. One-sixth of those with more than 1 g developed end-stage renal failure, while serum creatinine never exceeded 2 mg/dl in any with mild proteinuria. "Renal survival" (serum creatinine of 2 mg/dl or less) at five years after presentation was 100% in patients with persistently mild proteinuria, 87% in those whose protein excretion reached the moderate range, and 69% when heavy or nephrotic range proteinuria developed. Of significance, only rarely did mild proteinuria at presentation increase to higher levels. A correlation existed between level of protein excretion and severity of mesangial, segmental or global proliferation, glomerulosclerosis, podocyte effacement, interstitial infiltration, tubular atrophy and vascular sclerosis, even in patients with unimpaired renal function. Moderate or heavy proteinuria typically preceded the onset of hypertension and occurred prior to the development of renal insufficiency. Our results underscore magnitude of proteinuria as an early marker of glomerular damage in the prognosis of IgA nephropathy.

Entities:  

Mesh:

Year:  1988        PMID: 3367561     DOI: 10.1038/ki.1988.57

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Recognition and management of IgA nephropathy.

Authors:  L S Ibels; A Z Gyory; R J Caterson; C A Pollock; J F Mahony; D A Waugh; S Coulshed
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 3.  IgA nephropathy in children and adults.

Authors:  N Yoshikawa; H Nakamura; H Ito
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Quantitative ultrastructural study of afferent and efferent arterioles in IgA glomerulonephritis and benign nephrosclerosis.

Authors:  Z Rázga; B Iványi; N Zidar; D Ferluga; S Sonkodi; J Ormos
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

5.  Quantitative study of mesangial injury with proteinuria induced by monoclonal antibody 1-22-3.

Authors:  H Kawachi; T Oite; F Shimizu
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

6.  Follow-up of renal function and urinary protein excretion in childhood IgA nephropathy.

Authors:  U B Berg; U C Widstam-Attorps
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

7.  Urinary protein excretion and renal function in children with IgA nephropathy.

Authors:  U C Widstam-Attorps; U B Berg
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

8.  A Case Report of IgA Nephropathy Coexisting with Focal Segmental Glomerulosclerosis.

Authors:  Hassaan Iftikhar; Maryam Saleem; Anand Kaji
Journal:  Cureus       Date:  2019-06-29

9.  Validation of the Oxford classification of IgA nephropathy: a single-center study in Korean adults.

Authors:  Hoyoung Lee; Sul Hee Yi; Mi Seon Seo; Jin Nam Hyun; Jin Seok Jeon; Hyunjin Noh; Dong Cheol Han; Seung Duk Hwang; So Young Jin; Soon Hyo Kwon
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

Review 10.  Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis.

Authors:  Yu-Hao Zhou; Li-Gong Tang; Shi-Lei Guo; Zhi-Chao Jin; Mei-Jing Wu; Jia-Jie Zang; Jin-Fang Xu; Chun-Fang Wu; Ying-Yi Qin; Qing Cai; Qing-Bin Gao; Shan-Shan Zhang; Dand-Hui Yu; Jia He
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.